Analysts Set Expectations for Heron Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Research analysts at Capital One Financial issued their Q1 2024 earnings estimates for shares of Heron Therapeutics in a research report issued on Tuesday, April 23rd. Capital One Financial analyst T. Chiang anticipates that the biotechnology company will earn ($0.09) per share for the quarter. Capital One Financial has a "Overweight" rating and a $6.00 price objective on the stock. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.22) per share. Capital One Financial also issued estimates for Heron Therapeutics' Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.28) EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.47 EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.08. The company had revenue of $34.23 million during the quarter, compared to the consensus estimate of $30.98 million.

Several other research analysts have also recently commented on the stock. StockNews.com raised shares of Heron Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, January 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $5.00 target price on shares of Heron Therapeutics in a report on Thursday, April 11th.

Heron Therapeutics Stock Down 3.8 %

Shares of HRTX traded down $0.10 during mid-day trading on Thursday, hitting $2.55. 2,197,081 shares of the company's stock were exchanged, compared to its average volume of 2,790,822. Heron Therapeutics has a 52 week low of $0.50 and a 52 week high of $3.22. The stock's 50-day simple moving average is $2.75 and its 200-day simple moving average is $1.96. The firm has a market cap of $383.34 million, a price-to-earnings ratio of -2.97 and a beta of 1.68.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HRTX. SG Americas Securities LLC bought a new position in Heron Therapeutics in the third quarter valued at approximately $31,000. Apeiron RIA LLC increased its stake in Heron Therapeutics by 59.6% in the third quarter. Apeiron RIA LLC now owns 83,000 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 31,000 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company's stock valued at $324,000 after acquiring an additional 16,467 shares during the last quarter. Dakota Wealth Management bought a new position in Heron Therapeutics in the third quarter valued at approximately $55,000. Finally, Bank of New York Mellon Corp increased its stake in Heron Therapeutics by 5.8% in the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company's stock valued at $364,000 after acquiring an additional 19,345 shares during the last quarter. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.